Clinical trials: Proton Pump Inhibitor
Helicobacter Infections
Endofaster Test for Helicobacter Pylori Detection in Patients on Proton Pump Inhibitor Therapy
H. pylori infection is the most important causative agent of gastritis, and subsequent atrophic gastritis. The endoscopic diagnosis of H. pylori infection relies on urease tests such as the Clo test.
- Trial name
- NCT02126722
- Testing
- Gastroscopy, EndoFaster test, Clo test
- Where
- United Kingdom
- Volunteers
- 150 people
- Sponsor
- Niso Biomed S.R.L.
Gastroesophageal Reflux Disease, Non Erosive Reflux Disease
Confocal Endomicroscopy for Non-Erosive Reflux Disease (CE NERD)
The purpose of this study is to find out if people who have non-erosive reflux disease (NERD) have changes the investigators can see with a microscope (called confocal endomicroscopy) that is used during endoscopy (a camera scope…
- Conditions
- Gastroesophageal Reflux Disease, Non Erosive Reflux Disease, Dyspepsia
- Trial name
- CE_NERD (NCT02039869)
- Testing
- Confocal endomicroscopy, Proton pump inhibitor, Sucralfate
- Where
- 3 sites in United States
- Sponsor
- Virginia Commonwealth University
Gastro-esophageal Reflux Disease
Translation and Validation of the PASS Test for GERD Patients With Partial Response to PPI: PASS-HK
The PASS test is only available and valid tool for the evaluation of persistent acid-related symptoms in patients receiving PPI therapy.
- Trial name
- NCT02437682
- Where
- Hong Kong
- Volunteers
- 100 people
- Sponsor
- Chinese University of Hong Kong
Gastrointestinal Erosions and/or Ulcers
Efficacy of Proton Pump Inhibitors in Gastrointestinal Erosions and/or Ulcers
The aim of this study is to collect the data of clinical efficacy and safety after the usage of bonoprazon and esomeprazole when the patients take NSAIDs more than 2 weeks and have gastrointestinal symptoms who have had…
- Trial name
- NCT03315676
- Testing
- Oral Bonoprazan, Oral Esomeprazol
- Where
- Japan
- Volunteers
- 124 people, healthy volunteers welcome
- Sponsor
- Shinshu University
Laryngopharyngeal Reflux Disease
Comparative Effectiveness of Alginate, Magaldrate, Sucralfate, Proton Pump Inhibitors, and Diet in Laryngopharyngeal Reflux Disease
The goal of this randomized controlled trial is to compare the effectiveness of different treatments for laryngopharyngeal reflux disease (LPRD) in adult patients with confirmed symptoms and signs of the condition.
- Trial name
- NCT07611162
- Testing
- Alginate, Magaldrate, Sucralfate
- Where
- Belgium
- Volunteers
- 800 people
- Sponsor
- University of Mons
Upper Gastrointestinal Bleeding
ASP (PPI_H2RA) Study-H2RA Versus PPI for the Prevention of Recurrent UGIB in High-risk Users of Low-dose ASA
Peptic ulcer bleeding associated with ASA or NSAIDs is a major cause of hospitalization in Hong Kong. The investigators previously showed that ASA or NSAIDs accounted for about half of all cases of hospitalizations for peptic…
- Trial name
- NCT01408186
- Testing
- Rabeprazole, Famotidine
- Where
- 8 sites in Hong Kong, Japan
- Volunteers
- 264 people
- Sponsor
- Chinese University of Hong Kong
Chronic Cough Caused by Gastroesophageal Reflux
Efficacy of Proton Pump Inhibitor for Chronic Cough Caused by Gastroesophageal Reflux; Double-blind, Placebo-controlled, Randomized Clinical Trial
Efficacy of proton pump inhibitor for chronic cough caused by gastroesophageal reflux; double-blind, placebo-controlled, randomized clinical trial
- Trial name
- NCT01888549
- Testing
- High-dose PPI, standard PPI
- Where
- South Korea
- Volunteers
- 48 people
- Sponsor
- Yonsei University
Drug Interaction
PPI and Clopidogrel Response
Clopidogrel, in combination with aspirin, is currently the recommended treatment for secondary prevention of ischemic events in high-risk patients and for prevention of coronary artery stent thrombosis.
- Trial name
- NCT01170533
- Testing
- omeprazole and pantoprazole
- Where
- United States
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- University of Florida
Helicobacter Pylori Infection
Efficacies of Hybrid and High-dose Dual Therapies for the First-line Anti-H Pylori Treatment
Both hybrid and high-dose dual therapies developed by the scholars from Taiwan can achieve a high eradication rate for clarithromycin-resistant strains, and have a great potential to replace bismuth quadruple therapy in the…
- Trial name
- NCT05152004
- Testing
- Pariet, Amolin, Klaricid
- Where
- Taiwan
- Volunteers
- 240 people
- Sponsor
- Chang Gung Memorial Hospital
Heartburn
Symptom Control Satisfaction With Proton Pump Inhibitor Regimen
The overall aim of this study is to assess if patients with persistent gastroesophageal reflux disease (GERD) symptoms receiving sub-optimal omeprazole dosing experience improvement in GERD symptoms when prescribed an optimal…
- Trial name
- NCT02623816
- Testing
- Optimal Dosing of Omeprazole
- Where
- United States
- Volunteers
- 64 people, healthy volunteers welcome
- Sponsor
- MetroHealth Medical Center
Heartburn, Dyspepsia
Primary carE PPi dEprescRibing Trial
Proton pump inibitors (PPIs) is a class of medications that reduce the acid secretion in the stomach. These medications are very effective to relieve symptoms of acid reflux for a well-identified group of diseases and conditions.
- Conditions
- Heartburn, Dyspepsia, Reflux
- Trial name
- PEPPER (NCT05629143)
- Testing
- de-prescription of PPI via intermittent scheme, de-prescription of PPI via on-demand scheme, Alginate
- Where
- Belgium
- Volunteers
- 724 people
- Sponsor
- Universitaire Ziekenhuizen KU Leuven
Reflux, Gastroesophageal, Achalasia
The Effect of Physiotherapy on Post POEM Reflux
Per-oral endoscopic myotomy has been used as a treatment method of esophageal achalasia. Patients who undergo POEM as a treatment of achalasia are often presented with development of reflux as a side effect of the surgery.
- Conditions
- Reflux, Gastroesophageal, Achalasia, Esophagitis
- Trial name
- NCT05326113
- Testing
- Physiotherapy, Control group
- Where
- Czechia
- Volunteers
- 30 people
- Sponsor
- Institute for Clinical and Experimental Medicine
GERD, Gastroesophageal Reflux
Observational Study of Anti-Reflux Surgery
The Anti-Reflux Surgical Study has been established to: Collect data about anti-reflux surgical treatment options (magnetic sphincter augmentation and Fundoplication) in everyday clinical practice Track the clinical course of…
- Conditions
- GERD, Gastroesophageal Reflux, Gastro Esophageal Reflux
- Trial name
- NCT01624506
- Where
- 21 sites in Austria, Germany and 2 more
- Volunteers
- 760 people
- Sponsor
- Torax Medical Incorporated
Peptic Ulcer, Ulcer Complications
Peptic Ulcer Disease in Ischemic Heart Patients Taking Aspirin and Clopidogrel With or Without Proton Pump Inhibitor
Studies showed that combined use of clopidogrel and aspirin had a 25 % reduction of risk on myocardial infarction and stroke in patients who undergone percutaneous coronary intervention (PCI) when compared with use of aspirin…
- Trial name
- NCT00854776
- Testing
- lansoprazole, aluminum hydroxide 334 mg and Mg hydroxide 166 mg
- Where
- Taiwan
- Volunteers
- 300 people
- Sponsor
- Taipei Veterans General Hospital, Taiwan
Gastroesophageal Reflux
Fexofenadine Use in Gastroesophageal Reflux Symptoms
The investigators wish to study the effectiveness of Fexofenadine (an over the counter allergy pill) for the treatment of gastroesophageal reflux symptoms in patients who still have symptoms despite being on a proton pump…
- Trial name
- NCT03425097
- Testing
- Fexofenadine
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- Stanford University
Healthy Participants
Comparing the Extent to Which Three Different Formulations of LY4100511 (DC-853) Are Made Available in the Body, Alone and in the Presence of a Drug That Reduces Stomach Acid
The main purpose of this study is to compare the bioavailability of 3 different formulations of LY4100511 and if the use of a proton pump inhibitor (PPI) alters the bioavailability of the 3 different formulations.
- Trial name
- NCT06916143
- Testing
- LY4100511, Rabeprazole
- Where
- 2 sites in United States
- Volunteers
- 1 people, healthy volunteers welcome
- Sponsor
- Eli Lilly and Company
Osteoarthritis, Rheumatoid Arthritis
Observational Study on Non-steroid Anti-inflammatory Drugs (NSAIDs) Treated Patients With Arthritic Disorder
The aim of this study is to find out how patients with osteoarthritis, rheumatoid arthritis and ankylosing spondylitis receiving NSAID-therapy are treated and managed by their doctor in usual clinical practice, how patients…
- Conditions
- Osteoarthritis, Rheumatoid Arthritis, Ankylosing Spondylitis
- Trial name
- EVIDENCE (NCT01176682)
- Where
- 244 sites in Belgium, France and 10 more
- Volunteers
- 1,149 people
- Sponsor
- AstraZeneca
Duodenal Ulcer
Ilaprazole for the Treatment of Duodenal Ulcer in Chinese Patients
Patients with endoscopically diagnosed active duodenal ulcer disease were enrolled in a randomized, double-blind, parallel and dose-ranging trial.
- Trial name
- NCT02847455
- Testing
- 5 mg ilaprazole, 10 mg ilaprazole, 10 mg Rabeprazole
- Volunteers
- 408 people
- Sponsor
- Livzon Pharmaceutical Group Inc.
Duodenal Ulcer
Comparison of TAK-438 (Vonoprazan) to Lansoprazole in the Treatment of Duodenal Ulcer Participants With or Without Helicobacter Pylori Infection
The purpose of this study is to demonstrate the non-inferior efficacy of TAK-438 versus lansoprazole in the treatment of participants with duodenal ulcer.
- Trial name
- NCT03050359
- Testing
- TAK-438, Lansoprazole, Bismuth-Containing Quadruple Therapy
- Where
- 81 sites in China, Philippines and 2 more
- Volunteers
- 533 people
- Sponsor
- Takeda
Mantle Cell Lymphoma, COVID-19
A Study in Healthy Subjects to Assess Bioavailability (Proportion of a Drug Which Enters the Circulation to Have an Active Effect) of Acalabrutinib Tablet and Protonpump Inhibitor Effect (Members of a Class of Medications That Inhibits in Gastric Acid Production) for Rabeprazole
This Phase 1 study is being conducted to support the clinical development of acalabrutinib in hospitalized patients who are unable to swallow acalabrutinib tablet or capsule due to respiratory failure, eg, they may require…
- Trial name
- NCT04564040
- Testing
- Acalabrutinib Treatment A, Acalabrutinib Treatment B, Acalabrutinib Treatment C
- Where
- Germany
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- AstraZeneca